TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied.~2. Patients must have a related donor who is either a one, two or three out of six antigen mismatch at the HLA-A;B;DR loci.~3. Patients without a well-matched unrelated donor or those who have a disease status that precludes a wait for an identified unrelated donor.~4. Patients must adequate organ function:~   * LVEF of \>45%~  * FVC or FEV1 \>45% of predicted~  * Adequate liver function as defined by a serum bilirubin \<1.8, AST or ALT \< 2.5X upper limit of normal~  * Serum creatinine \< 2.0 mg/dl or creatinine clearance of \> 40 ml/min~5. Performance status \> 60% (Karnofsky)~6. Patients must be willing to use contraception if they have childbearing potential~7. Able to give informed consent~Exclusion Criteria:~1. An eligible HLA-identical sibling donor.~2. Performance status \< 60% (Karnosfsky)~3. HIV positive~4. Active involvement of the central nervous system with malignancy~5. Psychiatric disorder that would preclude patients from signing an informed consent~6. Pregnancy~7. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haploidentical Allogeneic Transplantation (Type: EXPERIMENTAL): Patients undergoing hematopoietic stem cell transplant from a partially matched related donor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Is a premenopausal female aged 18 to 50 years old (inclusive) on the day of signing of the informed consent form.~2. Has agreed to use only study-specified analgesic medications during the study and is not known to be intolerant to these.~3. Has a diagnosis of endometriosis and has had, within 10 years prior to signing the informed consent form, surgical or direct visualization and/or histopathologic confirmation of endometriosis, for example, during a laparoscopy or laparotomy.~4. During the Run-In Period (35 to 70 days prior to treatment period) has a dysmenorrhea NRS score ≥ 4.0 on at least 2 days and~   1. Mean NMPP NRS score ≥ 2.5, or~  2. Mean NMPP NRS score ≥ 1.25 and NMPP NRS score ≥ 5.0 on ≥ 4 days.~Key Exclusion Criteria:~1. Has a history of chronic pelvic pain that is not caused by endometriosis.~2. Has any chronic pain or frequently recurring pain condition, other than endometriosis that is treated with opioids or requires analgesics for ≥ 7 days per month.~3. Has had surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit.~4. Has a history of or currently has osteoporosis or other metabolic bone disease.~5. Has a clinically significant gynecologic condition, other than endometriosis, identified during Screening or Run-In period transvaginal ultrasound or endometrial biopsy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Group A) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 24 weeks.
- Relugolix plus Delayed E2/NETA (Group B) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
- Placebo (Group C) (Type: PLACEBO_COMPARATOR): Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy.~2. Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired).~3. Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility.~Exclusion Criteria:~1. History of significant sensitivity or allergy to androgens, or product excipients.~2. Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up.~3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s).~4. Subjects with symptoms of moderate to severe benign prostatic hyperplasia.~5. Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis~6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).~7. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.~8. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.~9. History of stroke or myocardial infarction within the past 5 years.~10. History of or current or suspected prostate or breast cancer.~11. History of untreated and severe obstructive sleep apnea.~12. History of long QT syndrome (QTc \> 450) or unexplained sudden death in a first degree relative (parent, sibling, or child).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral testosterone undecanoate, LPCN 1021 (Type: EXPERIMENTAL): Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children (6 to \< 12 years of age and/or weighing 17.5 to \< 35 Kg).~* Chronic HCV genotype 4 infection for at least 6 months without cirrhosis (confirmed by Fibroscan).~* Naïve patients to previous anti-HCV treatment.~* Diagnosed with hematological malignancy and on maintenance chemotherapy.~Exclusion Criteria:~* Known hypersensitivity to any of the study medications.~* Ongoing treatment with any interacting medications like carbamazepine, fosphenytoin, phenytoin, oxcarbazepine, phenobarbital, and rifampin.~* History of any comorbid illness that may interfere with the pharmacokinetics of the study drugs or prohibit the compliance with the study protocol such as;~  1. Decompensated liver disease as shown by the presence of ascites, encephalopathy, or a history of variceal hemorrhage.~ 2. The ongoing treatment of other types of cancer or blood disorders.~ 3. Co-infection with human immunodeficiency virus (HIV), or hepatitis B virus.~ 4. Renal dysfunction.~ 5. Active infection that is currently producing symptoms.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- HCV-infected patients with hematological malignancy (Type: ACTIVE_COMPARATOR): HCV-infected patients with hematological malignancy on maintenance chemotherapy
- Control HCV-infected patients (Type: ACTIVE_COMPARATOR): Control HCV-infected patients without haematological malignancy or co-morbidities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Able to speak and read in English~3. Physician confirmed RA define by 1987 American College of Rheumatology criteria~4. Moderate or highly active rheumatoid arthritis (assess by Routine Assessment of Patient Index Data 3 (RAPID3) score \> 2.0) and~5. Physician indicates patient is a candidate for initiation or escalation of Disease-modifying antirheumatic drug (DMARD) therapy~Exclusion Criteria:~1. Hearing or visually impaired

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Other CMI Only (Type: ACTIVE_COMPARATOR): Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
- Other CMI & SMART Program (Type: EXPERIMENTAL): Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
- Drug Facts Boxes Only (Type: EXPERIMENTAL): Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
- Drug Facts Boxes & SMART Program (Type: EXPERIMENTAL): Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hearing Aid Signal Processing Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe sensorineural hearing loss~* Current hearing aid user~Exclusion Criteria:~* Lack of willingness to wear study devices for approximately one month~* Inability to travel to study appointments or to complete questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- A-B-A (Type: EXPERIMENTAL): Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument A Hearing instrument B Hearing instrument A
- B-A-B (Type: EXPERIMENTAL): Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument B Hearing instrument A Hearing instrument B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms~* Subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline~* Subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics~Exclusion Criteria:~* Subjects who are moribund with an expected survival of less than 2 weeks.~* Subjects who have been designated as Do Not Resuscitate, unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy~* Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Type 2 diabetes - Age above or equal to 50 years with predefined previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined cardiovascular risk factors - HbA1c (glycosylated haemoglobin) above or equal to 7.0% or HbA1c below 7.0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day - One or more oral or injectable antidiabetic agent(s) Exclusion Criteria: - An acute coronary or cerebrovascular event in the previous 60 days - Planned coronary, carotid or peripheral artery revascularisation - Chronic heart failure NYHA (New York Heart Association) class IV - Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec (IDeg) (Type: EXPERIMENTAL): All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
- Insulin glargine (IGlar) (Type: ACTIVE_COMPARATOR): All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Men or women of any racial background~* healthy~* sealevel resident~* age \>= 18 years, =\< 65 years~* SBP\< 130 mmHg and DBP\< 80 mmHg, average of two measures at the sceening visit~* FG \< 100 mg/dl (5.6 mmol/l)~* BMI \< 25~* written informed consent signed~Exclusion Criteria~* engagement in regular exercise training~* smoking habit~* being enrolled in another research study~* any current or previous cardiovascular, metabolic disease or any other cronic disease~* any current treatment for any medical condition~* any medical condition preventing or contraindication exposure to altitude hypoxia~* any gastrointestinal disorder interfering with drug absorption~* known allergy or contraindications to beta-blockers~* pregnant or lactating women; women in reproductive age not using recognized contraceptive methods.~* malignancy within the last 5 years~* drug abuse or alcohol abuse within the last 5 years~* history of noncompliance to medical regimens~* incapacity or unwillingness to sign the informed consent~* participation in any investigational clinical trial within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablets. One tablet twice daily.
- 2: Carvedilol (Type: ACTIVE_COMPARATOR): Carvedilol 25 mg tablets. One tablet twice daily.
- 3: Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 20 and 80 years old~* With multiple myeloma in 2nd or later relapse or showing resistance after 2 treatment lines~* Eastern Cooperative Oncology Group (ECOG) ≤ 2~* Life expectancy greater than six months~* Creatinine clearance rate more than 30 ml / min~* Subjects who have received at least 4 cycles of rescue treatment under the procedures of the 12 de Octubre Hospital (rescue treatment will vary depending on previous anti-myeloma treatment). After treatment, patients must have shown chemosensitivity and disease stabilization.~* Will be included subjects with partial response or stable disease (for at least 2 cycles) after 75% of planned rescue treatment or patients at subclinical progression (defined as an increase of monoclonal component ≥ 25%) at any time of rescue treatment. Subjects have to show tolerance to rescue treatment, without G3/4 adverse effects, if G1/2 adverse effects exist they must be analyzed immediately before starting reinfusion program.~* Subjects have to agree to participate in the trial and they have to sign informed consent.~Exclusion Criteria:~* Subjects with clinical progression or complete response will not be included.~* Any of the following abnormal laboratory results:~Absolute Neutrophil Count \< 1000/ µL Platelets Count \< 50000/ µL in those patients with bone marrow infiltration lower than 50% Measured creatinine clearance \<30 ml/min Hemoglobin level ≤ 8 g/dL Peripheral neuropathy ≥ Grade 2~* Subjects have received allogeneic stem cell transplant.~* Subjects with heart disease which compromises patient's life or protocol accomplishment.~* Subjects with past clinical history of malignant disease within 3 years (exceptions are squamous or basal cell carcinoma).~* Subjects receiving another investigational drug or having received investigational drug within 30 days before screening.~* Subjects who require chronic steroid or immunosuppressive treatment.~* Any condition, including abnormally laboratory results, that might compromise the patient´s life if he participate in this study.~* Any concurrent medical condition, abnormally laboratory results or any psychological disorder that prevent the patient to sign the informed consent.~* Pregnant or fertile women.~* Patients known to be seropositive for human immunodeficiency virus (VIH) or having active hepatitis A, B or C.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NKAE cells infusion + chemotherapy (Type: EXPERIMENTAL): Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis due to grass or birch pollen~* Mild to moderate asthma with a positive methacholine challenge~* Accepted and signed informed consent.~Exclusion Criteria:~* Previously subcutaneous immunotherapy (SCIT) with total symptom relief.~* Previously SCIT but no symptom improvement at all.~* Sensitizations to house dust mite or furry animals, with ongoing exposure and symptoms.~* Severe atopic dermatitis.~* Patients with significant diseases other than allergic rhinitis. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.~* Patients with a respiratory tract infection in the past 4 weeks prior to Visit 2.~* Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants).~* Known autoimmune or collagen disease~* Cardiovascular disease~* Hepatic disease~* Known renal insufficiency~* Cancer~* Hematologic disease~* Chronic infectious disease~* Any medication with a possible side-effect of interfering with the immune response~* Previous immuno- or chemotherapy~* Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with β-blockers)~* Major metabolic disease~* Known or suspected allergy to the study product~* Obesity with BMI \> 30 since subcutaneous fat makes ultrasound imaging of lymph nodes harder which may risk the correct placement of injection.~* Patients who, in the opinion of the investigator, abuse alcohol or drugs within 2 years prior to Visit 1.~* Patients who have taken an investigational drug within 1 month or six half lives, whichever is greater, prior to Visit 1.~* Mental incapability of coping with the study~* Withdrawal of informed consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): ALK diluent 0,3% human albumin'
- Active treatment (Type: EXPERIMENTAL): Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete